Hyperglycemia management in patients with posttransplantation diabetes

Rodolfo J. Galindo, Martin Fried, Tracy Breen, Ronald Tamler

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Objective: Posttransplantation diabetes (PTDM) is a common occurrence after solid-organ transplantation and is associated with increased morbidity, mortality, and health care costs. There is a limited number of studies addressing strategies for hyperglycemia management in this population, with a few articles emerging recently. Methods: We performed a PubMed search of studies published in English addressing hyperglycemia management of PTDM/new-onset diabetes after transplant (NODAT). Relevant cited articles were also retrieved. Results: Most of the 25 publications eligible for review were retrospective studies. Insulin therapy during the early posttransplantation period showed promise in preventing PTDM development. Thiazolidinediones have been mostly shown to exert glycemic control in retrospective studies, at the expense of weight gain and fluid retention. Evidence with metformin, sulfonylureas, and meglitinides is very limited. Incretins have shown promising results in small prospective studies using sitagliptin, linaglitpin, and vildagliptin and a case series using liraglutide. Conclusion: Prospective randomized studies assessing the management of hyperglycemia in PTDM are urgently needed. In the meantime, clinicians need to be aware of the high risk of PTDM and associated complications and current concepts in management.

Original languageEnglish
Pages (from-to)454-465
Number of pages12
JournalEndocrine Practice
Issue number4
StatePublished - Apr 2016
Externally publishedYes


Dive into the research topics of 'Hyperglycemia management in patients with posttransplantation diabetes'. Together they form a unique fingerprint.

Cite this